Autism Spectrum Disorder

Autism Spectrum Disorder

ICD-10: F84.0 | ICD-11: 6A02 | Prevalence: ~1 in 36 children (US, 2023)

Overview

Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition defined by persistent differences in social communication and by restricted or repetitive behaviors and interests[@siblings]. Although ASD is not a neurodegenerative disease, it intersects with NeuroWiki because many of the implicated pathways, including synaptic transmission, epigenetic regulation, and circuit development, overlap with mechanisms studied across neurologic disease[@siblings][@vaetfa].

ASD represents a spectrum of conditions characterized by:

• Social communication deficits
• Restricted and repetitive behaviors
• Narrow interests
• Sensory hypersensitivity or hyposensitivity

Epidemiology

Prevalence

ASD prevalence has increased significantly over recent decades, attributed to broader diagnostic criteria, increased awareness, and potential environmental factors[@siblings][@eating]:

• United States: Approximately 1 in 36 children (2023 CDC estimate)
• Global: Estimated 1 in 100 children worldwide (WHO)
• Gender ratio: Males are diagnosed 4-5x more frequently than females
• Age of diagnosis: Median age of diagnosis is 4-5 years, though earlier identification is possible

Risk Factors

Risk factors for ASD include[@siblings][@eating]:

Autism Spectrum Disorder

ICD-10: F84.0 | ICD-11: 6A02 | Prevalence: ~1 in 36 children (US, 2023)

Overview

Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition defined by persistent differences in social communication and by restricted or repetitive behaviors and interests[@siblings]. Although ASD is not a neurodegenerative disease, it intersects with NeuroWiki because many of the implicated pathways, including synaptic transmission, epigenetic regulation, and circuit development, overlap with mechanisms studied across neurologic disease[@siblings][@vaetfa].

ASD represents a spectrum of conditions characterized by:

• Social communication deficits
• Restricted and repetitive behaviors
• Narrow interests
• Sensory hypersensitivity or hyposensitivity

Epidemiology

Prevalence

ASD prevalence has increased significantly over recent decades, attributed to broader diagnostic criteria, increased awareness, and potential environmental factors[@siblings][@eating]:

• United States: Approximately 1 in 36 children (2023 CDC estimate)
• Global: Estimated 1 in 100 children worldwide (WHO)
• Gender ratio: Males are diagnosed 4-5x more frequently than females
• Age of diagnosis: Median age of diagnosis is 4-5 years, though earlier identification is possible

Risk Factors

Risk factors for ASD include[@siblings][@eating]:

• Genetic factors: Heritability estimated at 60-90%
• Advanced parental age: Both maternal and paternal
• Premature birth: Especially before 35 weeks gestation
• Prenatal exposures: Certain medications, toxins
• Sibling risk: Higher risk in families with one affected child

Genetics of ASD

High-Impact Rare Variants

Several monogenic causes of ASD have been identified[@gintransformer][@knowledge]:

| Gene | Function | Phenotype |
|------|----------|------------|
| FMR1 | Fragile X mental retardation protein | Intellectual disability, macroorchidism |
| SHANK3 | Synaptic scaffolding | Speech/language deficits |
| NRXN1 | Cell adhesion molecule | Variable neurodevelopmental phenotypes |
| CNTNAP2 | Neurexin family | Language regression, seizures |
| 16p11.2 | Chromosomal deletion | Variable expressivity |

Common Variant Architecture

Genome-wide studies have identified hundreds of common variants with small effect sizes, collectively contributing to ASD risk[@gintransformer]:

• Genes enriched for synaptic function
• Chromatin regulation genes
• Neuronal development pathways

Copy Number Variants

Pathogenic CNVs account for 10-20% of simplex ASD cases[@gintransformer]:

• 16p11.2 deletion/duplication
• 15q11-q13 (Prader-Willi/Angelman region)
• 22q11.2 deletion (DiGeorge syndrome)

Neurobiological Mechanisms

Synaptic Dysfunction

Synaptic pathology is a central feature of ASD[@vaetfa][^6]:

Postsynaptic density abnormalities:

• SHANK3 mutations disrupt PSD structure
• Altered NMDA and AMPA receptor trafficking
• Impaired synaptic plasticity mechanisms

• Neurexin and neuroligin mutations
• Altered vesicle release kinetics
• Synaptic vesicle cycle defects

Excitation-Inhibition Imbalance

The E/I balance hypothesis posits that ASD involves altered ratio of excitatory to inhibitory signaling[@vaetfa][^6]:

• GABAergic dysfunction: Reduced GABA receptor signaling
• Glutamate excitotoxicity: Altered AMPA/kainate receptors
• Circuit-level effects: Impaired neural oscillation patterns
• Treatment implications: GABAergic agents under investigation

Neuroinflammation

Increasing evidence supports immune dysfunction in ASD[^7][^8]:

• Microglial activation: Increased IBA-1 staining in postmortem brain
• Cytokine profiles: Altered IL-6, TNF-α, IL-1β in CSF/blood
• Maternal immune activation: Animal models show ASD-like behaviors
• [Blood-brain barrier](/entities/blood-brain-barrier): Potential disruption in some cases

Epigenetic Regulation

Epigenetic mechanisms contribute to ASD pathogenesis[^9]:

• [DNA methylation](/entities/dna-methylation): Altered patterns in ASD brain
• [Histone modifications](/entities/histone-modifications): Dysregulated chromatin states
• Non-coding RNAs: miRNA expression abnormalities
• Imprinting effects: Parent-of-origin effects

Connection to Neurodegenerative Diseases

Shared Genetic Architecture

Several genes implicated in ASD also play roles in neurodegenerative diseases[@gintransformer][^10]:

| ASD Gene | Neurodegenerative Relevance |
|----------|----------------------------|
| FMR1 | Fragile X-associated disorders |
| SHANK3 | Linked to Rett syndrome |
| NRXN1 | Interacts with [α-synuclein](/proteins/alpha-synuclein) |
| [MAPT](/proteins/tau) | Associated with tauopathies |

Comorbidity

ASD frequently co-occurs with[@siblings][@eating]:

• Intellectual disability: ~30-50% of ASD cases
• Epilepsy: 5-30% prevalence, bidirectional relationship
• Attention-deficit/hyperactivity disorder (ADHD): ~50% comorbidity
• Anxiety disorders: Up to 40% in verbal individuals

Synaptic Protein Overlap

The synaptic protein networks implicated in ASD overlap with those affected in AD, PD, and ALS[^10]:

• Postsynaptic density proteins (SHANK family)
• Synaptic adhesion molecules (neurexin, neuroligin)
• Cytoskeletal regulators (actin, microtubules)

Treatment Approaches

Behavioral Interventions

Evidence-based behavioral treatments include[@siblings][@eating]:

• Applied behavior analysis (ABA): Structured skill building
• Social skills training: Group-based interventions
• Occupational therapy: Sensory integration
• Speech/language therapy: Communication enhancement
• Early intensive behavioral intervention (EIBI): Comprehensive approach

Pharmacological Approaches

No drugs treat core ASD symptoms, but medications address co-occurring conditions[@siblings][^11]:

| Target | Medications | Indication |
|--------|-------------|------------|
| Irritability/ aggression | Risperidone, aripiprazole | FDA-approved for ASD |
| ADHD symptoms | Stimulants, atomoxetine | Attention/impulsivity |
| Anxiety | SSRIs | Anxiety/OCD features |
| Seizures | Antiepileptics | Epilepsy |

Emerging Therapies

Novel approaches under investigation include[^11][^12]:

• MGluR5 antagonists: Targeting glutamate signaling
• GABAergic agents: Addressing E/I imbalance
• Oxytocin: Social cognition enhancement
• Stem cell therapy: Limited evidence to date
• Gene therapy: For monogenic forms (FMR1, SHANK3)

Cross-Links to Related Mechanisms

• [Synaptic Transmission](/mechanisms/synaptic-transmission) — Synaptic dysfunction
• [Neuroinflammation](/mechanisms/neuroinflammation) — Inflammatory mechanisms
• [Epigenetic Regulation](/mechanisms/epigenetic-regulation) — Gene-environment interactions
• [Neurodevelopment](/mechanisms/neurodevelopment) — Developmental origins
• [Excitotoxicity in Neurodegeneration](/excitotoxicity-in-neurodegeneration) — Glutamate signaling

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Intellectual Disability](/diseases/intellectual-disability)
• [Epilepsy](/diseases/epilepsy)
• [Fragile X Syndrome](/diseases/fragile-x-syndrome)

Key Publications

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• ["Am I My Sibling's Keeper?": the Lived experiences of adult siblings of individuals with Autism Spectrum Disorder in China.](https://pubmed.ncbi.nlm.nih.gov/41627191/) (2026 Dec 31) - International journal of qualitative studies on health and well-being
• [VaeTF-A community-aware perceptual architecture for detecting autism spectrum disorders using fMRI.](https://pubmed.ncbi.nlm.nih.gov/41613420/) (2026 Dec) - Cognitive neurodynamics
• [Eating behaviours of children with ASD: Associations with parental stress, perceived symptom severity, and parenting style in a sample from Türkiye.](https://pubmed.ncbi.nlm.nih.gov/41643942/) (2026 Jun 1) - Appetite
• [GIN-transformer based pairwise graph contrastive learning framework.](https://pubmed.ncbi.nlm.nih.gov/41576557/) (2026 Jun) - Neural networks : the official journal of the International Neural Network Society
• [Knowledge, support, and networking for Phelan-McDermid syndrome: a study protocol.](https://pubmed.ncbi.nlm.nih.gov/41551253/) (2026 Jun) - MethodsX

References

External

• [Autism Speaks](https://www.autismspeaks.org/)
• [NIH Autism](https://www.ni

Pathway Diagram

Key molecular relationships involving Autism Spectrum Disorder from the SciDEX knowledge graph: